bio-state Inc.

GM Test

FungiXpert®

Aspergillus Galactomannan ELISA Detection Kit

Product code: FGM096-001

Obtain result in 2h

Overview

The incidence of Invasive Aspergillosis (IA) in immunosuppressed patients is rapidly increasing due to antibiotic abuse. *Aspergillus fumigatus* is one of the most common pathogens that cause severe aspergillus infection in patients with immunosuppressive disease, followed by *Aspergillus flavus, Aspergillus niger* and *Aspergillus terreus*. Due to lack of typical clinical manifestations and effective early diagnosis methods, IA has a high mortality rate of 60% to 100%. FungiXpert® Aspergillus Galactomannan ELISA Detection Kit is used to detect galactomannan for the early diagnosis of invasive aspergillus infection.

Product Characteristics

Basic Parameters	Aspergillus Galactomannan ELISA Detection Kit
Method	ELISA
Sample Type	Serum, BAL fluid
Sample Volume	300 μL
Specification	96 tests/kit
Detection Time	2 h
Detection Objects	*Aspergillus spp.*
Stability	The kit is stable for 1 years at 2℃-8℃
Limit of Detection	0.5 ng/ml

Validated on
Fully automatic
DYNEX DS2

Product Advantages

More Advance

International leading edge detection method, high sensitivity and specificity

More Accurate

Optimize the operation step, reduce the risk of contamination during the experiment

Faster

One-step detection, reducing the number of incubation and washing

Obtain results within 2 hours

More Economical

Split microplate, cost saving

Clinical Performance

- **Low detection limit**

  Limit of Detection (LoD) is 0.5 ng/ml

- **Sensitivity and specificity**

|	Serum	BAL
Sensitivity	89.8%	92.4%
Specificity	90.7%	94.1%

- **Support the diagnosis of invasive aspergillosis in early stage (Pazos et al., 2005)**

  GM is 5-8 days earlier than the clinical symptoms of invasive aspergillosis (IA);

  GM is 7.2 days earlier than high-resolution CT scans;

  GM is on average 12.5 days earlier than starting empirical antifungal treatment.

- **Monitor disease progression and therapeutic response, and predict outcome**
  (Pazos et al., 2005)

- **Recommendations**

  Recommended by IDSA guideline for Aspergillosis 2016 (Patterson et al., 2016) and
  ESCMID-ECMM-ERS guideline for Aspergillosis 2018 (Ullmann et al., 2017)

Innovation for Better Health

For more information contact :

bio-state Inc.

16, G. F, Arjun Arcade Phase - 1, Shopping Complex, Sector 30 & 33 Faridabad - 121003, Haryana (Delhi/NCR)
Mob. : +91 9654454435, 9654454425 Email. : nitin.gupta@bio-state.com Website. : www.bio-state.com